Alpha7 nicotinic cholinergic neuromodulation may reconcile multiple neurotransmitter hypotheses of schizophrenia

Medical Hypotheses

Volumn 78, Issue 5, 2012, Pages 594-600

  Bencherif, Merouane ^a   Stachowiak, Michal K ^b   Kucinski, Aaron J ^b   Lippiello, Patrick M ^a  

^a TARGACEPT INC   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; BUNGAROTOXIN RECEPTOR; DOPAMINE; GLUTAMIC ACID; NEUROTRANSMITTER;

ANHEDONIA; ARTICLE; BLUNTED AFFECT; BRAIN REGION; COGNITIVE DEFECT; DELUSION; GENETIC LINKAGE; HALLUCINATION; HUMAN; MESOLIMBIC DOPAMINERGIC SYSTEM; NEGATIVE SYNDROME; NEUROMODULATION; PATHOGENESIS; POSITIVE SYNDROME; SCHIZOPHRENIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; CHOLINERGIC AGONISTS; DOPAMINE; GAMMA-AMINOBUTYRIC ACID; GLUTAMIC ACID; HUMANS; MODELS, NEUROLOGICAL; RECEPTORS, NICOTINIC; SCHIZOPHRENIA;

EID: 84859270307     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2012.01.035     Document Type: Article

References (72)

1. Stone J.M., Morrison P.D., Pilowsky L.S. Glutamate and dopamine dysregulation in schizophrenia-a synthesis and selective review. J Psychopharmacol 2007, 21:440-452.
2. Money T.T., Scarr E., Udawela M., Gibbons A.S., Jeon W.J., Seo M.S., et al. Treating schizophrenia: novel targets for the cholinergic system. CNS Neurol Disord Drug Targets 2009.
3. Harrison P.J. Dopamine and schizophrenia-proof at last?. Lancet 2000, 356:958-959.
4. Wong A.H., Van Tol H.H. Schizophrenia: from phenomenology to neurobiology. Neurosci Biobehav Rev 2003, 27:269-306.
5. Kugaya A., Fujita M., Innis R.B. Applications of SPECT imaging of dopaminergic neurotransmission in neuropsychiatric disorders. Ann Nucl Med 2000, 14:1-9.
6. Bogerts B., Lieberman J.A., Bilder R.M., Ashtari M., Degreef G., Lerner G., et al. A volumetric MRI study of limbic structures in chronic schizophrenia-relationship to psychopathology. Clin Neuropharmacol 1992, 15(Suppl 1 Pt A):112A-113A.
7. Lewis D.A., Gonzalez-Burgos G. Intrinsic excitatory connections in the prefrontal cortex and the pathophysiology of schizophrenia. Brain Res Bull 2000, 52:309-317.
8. Geyer M.A. Developing translational animal models for symptoms of schizophrenia or bipolar mania. Neurotox Res 2008, 14:71-78.
9. Seeman P., Weinshenker D., Quirion R., Srivastava L.K., Bhardwaj S.K., Grandy D.K., et al. Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis. Proc Natl Acad Sci USA 2005, 102:3513-3518.
10. Kapur S., Zipursky R., Jones C., Remington G., Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000, 157:514-520.
11. Mishara A.L., Goldberg T.E. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biol Psychiatry 2004, 55:1013-1022.
12. Moghaddam B. Bringing order to the glutamate chaos in schizophrenia. Neuron 2003, 40:881-884.
13. Verma A., Moghaddam B. NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine. J Neurosci 1996, 16:373-379.
14. Dudkin K.N., Kruchinin V.K., Chueva I.V. Neurophysiological correlates of delayed visual differentiation tasks in monkeys: the effects of the site of intracortical blockade of NMDA receptors. Neurosci Behav Physiol 2001, 31:207-218.
15. Coyle J.T. The GABA-glutamate connection in schizophrenia: which is the proximate cause?. Biochem Pharmacol 2004, 68:1507-1514.
16. Adler C.M., Malhotra A.K., Elman I., Goldberg T., Egan M., Pickar D., et al. Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am J Psychiatry 1999, 156:1646-1649.
17. Olney J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995, 52:998-1007.
18. Laruelle M., Kegeles L.S., bi-Dargham A. Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment. Ann N Y Acad Sci 2003, 1003:138-158.
19. Carlsson A., Waters N., Carlsson M.L. Neurotransmitter interactions in schizophrenia-therapeutic implications. Biol Psychiatry 1999, 46:1388-1395.
20. Behrendt R.P. Dysregulation of thalamic sensory " transmission" in schizophrenia: neurochemical vulnerability to hallucinations. J Psychopharmacol 2006, 20:356-372.
21. Moghaddam B., Adams B., Verma A., Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 1997, 17:2921-2927.
22. Sharp F.R., Tomitaka M., Bernaudin M., Tomitaka S. Psychosis: pathological activation of limbic thalamocortical circuits by psychomimetics and schizophrenia?. Trends Neurosci 2001, 24:330-334.
23. Rowland L.M., Bustillo J.R., Mullins P.G., Jung R.E., Lenroot R., Landgraf E., et al. Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study. Am J Psychiatry 2005, 162:394-396.
24. Tamminga C.A., Stan A.D., Wagner A.D. The hippocampal formation in schizophrenia. Am J Psychiatry 2010, 167:1178-1193.
25. Lisman J.E., Pi H.J., Zhang Y., Otmakhova N.A. A thalamo-hippocampal-ventral tegmental area loop may produce the positive feedback that underlies the psychotic break in schizophrenia. Biol Psychiatry 2010, 68:17-24.
26. Floresco S.B., Todd C.L., Grace A.A. Glutamatergic afferents from the hippocampus to the nucleus accumbens regulate activity of ventral tegmental area dopamine neurons. J Neurosci 2001, 21:4915-4922.
27. Goto Y., Grace A.A. Limbic and cortical information processing in the nucleus accumbens. Trends Neurosci 2008, 31:552-558.
28. Boyer P., Phillips J.L., Rousseau F.L., Ilivitsky S. Hippocampal abnormalities and memory deficits: new evidence of a strong pathophysiological link in schizophrenia. Brain Res Rev 2007, 54:92-112.
29. Sagud M., Mihaljevic-Peles A., Muck-Seler D., Pivac N., Vuksan-Cusa B., Brataljenovic T., et al. Smoking and schizophrenia. Psychiatr Danub 2009, 21:371-375.
30. Holden C. Neuroscience. Deconstructing schizophrenia. Science 2003, 299:333-335.
31. Esterberg M.L., Compton M.T. Smoking behavior in persons with a schizophrenia-spectrum disorder: a qualitative investigation of the transtheoretical model. Soc Sci Med 2005, 61:293-303.
32. DeLuca V., Wong A.H., Muller D.J., Wong G.W., Tyndale R.F., Kennedy J.L. Evidence of association between smoking and alpha7 nicotinic receptor subunit gene in schizophrenia patients. Neuropsychopharmacology 2004, 29:1522-1526.
33. Avila M.T., Sherr J.D., Hong E., Myers C.S., Thaker G.K. Effects of nicotine on leading saccades during smooth pursuit eye movements in smokers and nonsmokers with schizophrenia. Neuropsychopharmacology 2003, 28:2184-2191.
34. Harris J.G., Kongs S., Allensworth D., Martin L., Tregellas J., Sullivan B., et al. Effects of nicotine on cognitive deficits in schizophrenia. Neuropsychopharmacology 2004, 29:1378-1385.
35. Levin E.D., Wilson W., Rose J.E., McEvoy J. Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology 1996, 15:429-436.
36. Bidzan L. A review of the effects of nicotine on schizophrenia. Psychiatr Pol 2007, 41:737-744.
37. Taly A., Corringer P.J., Guedin D., Lestage P., Changeux J.P. Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system. Nat Rev Drug Discov 2009, 8:733-750.
38. Buchanan R.W., Freedman R., Javitt D.C., bi-Dargham A., Lieberman J.A. Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Schizophr Bull 2007, 33:1120-1130.
39. Paterson D., Nordberg A. Neuronal nicotinic receptors in the human brain. Prog Neurobiol 2000, 61:75-111.
40. Martin L.F., Freedman R. Schizophrenia and the alpha7 nicotinic acetylcholine receptor. Int Rev Neurobiol 2007, 78:225-246.
41. Freedman R., Adams C.E., Leonard S. The alpha7-nicotinic acetylcholine receptor and the pathology of hippocampal interneurons in schizophrenia. J Chem Neuroanat 2000, 20:299-306.
42. Hauser T.A., Kucinski A., Jordan K.G., Gatto G.J., Wersinger S.R., Hesse R.A., et al. TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia. Biochem Pharmacol 2009, 78:803-812.
43. Toyohara J., Hashimoto K. Alpha7 nicotinic receptor agonists: potential therapeutic drugs for treatment of cognitive impairments in schizophrenia and alzheimer's disease. Open Med Chem J 2010, 4:37-56.
44. Koike K., Hashimoto K., Takai N., Shimizu E., Komatsu N., Watanabe H., et al. Tropisetron improves deficits in auditory P50 suppression in schizophrenia. Schizophr Res 2005, 76:67-72.
45. Livingstone P.D., Wonnacott S. Nicotinic acetylcholine receptors and the ascending dopamine pathways. Biochem Pharmacol 2009, 78:744-755.
46. Dani J.A., Bertrand D. Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu Rev Pharmacol Toxicol 2007, 47:699-729.
47. Dickinson J.A., Kew J.N., Wonnacott S. Presynaptic alpha 7- and beta 2-containing nicotinic acetylcholine receptors modulate excitatory amino acid release from rat prefrontal cortex nerve terminals via distinct cellular mechanisms. Mol Pharmacol 2008, 74:348-359.
48. Arnaiz-Cot J.J., Gonzalez J.C., Sobrado M., Baldelli P., Carbone E., Gandia L., et al. Allosteric modulation of alpha 7 nicotinic receptors selectively depolarizes hippocampal interneurons, enhancing spontaneous GABAergic transmission. Eur J Neurosci 2008, 27:1097-1110.
49. Quarta D., Naylor C.G., Barik J., Fernandes C., Wonnacott S., Stolerman I.P. Drug discrimination and neurochemical studies in alpha7 null mutant mice. tests for the role of nicotinic alpha7 receptors in dopamine release. Psychopharmacology (Berl) 2008, 203:399-410.
50. Bitner R.S., Bunnelle W.H., Anderson D.J., Briggs C.A., Buccafusco J., Curzon P., et al. Broad-spectrum efficacy across cognitive domains by alpha7 nicotinic acetylcholine receptor agonism correlates with activation of ERK1/2 and CREB phosphorylation pathways. J Neurosci 2007, 27:10578-10587.
51. Mansvelder H.D., McGehee D.S. Long-term potentiation of excitatory inputs to brain reward areas by nicotine. Neuron 2000, 27:349-357.
52. Maskos U. The cholinergic mesopontine tegmentum is a relatively neglected nicotinic master modulator of the dopaminergic system: relevance to drugs of abuse and pathology. Br J Pharmacol 2008, 153(Suppl 1):S438-S445.
53. Azam L., Winzer-Serhan U.H., Chen Y., Leslie F.M. Expression of neuronal nicotinic acetylcholine receptor subunit mRNAs within midbrain dopamine neurons. J Comp Neurol 2002, 444:260-274.
54. Quik M., Polonskaya Y., Gillespie A., Jakowec M., Lloyd G.K., Langston J.W. Localization of nicotinic receptor subunit mRNAs in monkey brain by in situ hybridization. J Comp Neurol 2000, 425:58-69.
55. Sydserff S., Sutton E.J., Song D., Quirk M.C., Maciag C., Li C., et al. Selective alpha7 nicotinic receptor activation by AZD0328 enhances cortical dopamine release and improves learning and attentional processes. Biochem Pharmacol 2009, 78:880-888.
56. bi-Dargham A., Gil R., Krystal J., Baldwin R.M., Seibyl J.P., Bowers M., et al. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 1998, 155:761-767.
57. Carlsson A., Waters N., Holm-Waters S., Tedroff J., Nilsson M., Carlsson M.L. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu Rev Pharmacol Toxicol 2001, 41:237-260.
58. Marchi M., Risso F., Viola C., Cavazzani P., Raiteri M. Direct evidence that release-stimulating alpha7i nicotinic cholinergic receptors are localized on human and rat brain glutamatergic axon terminals. J Neurochem 2002, 80:1071-1078.
59. Toth E., Sershen H., Hashim A., Vizi E.S., Lajtha A. Effect of nicotine on extracellular levels of neurotransmitters assessed by microdialysis in various brain regions: role of glutamic acid. Neurochem Res 1992, 17:265-271.
60. Fang X., Stachowiak E.K., Dunham-Ems S.M., Klejbor I., Stachowiak M.K. Control of CREB-binding protein signaling by nuclear fibroblast growth factor receptor-1: a novel mechanism of gene regulation. J Biol Chem 2005, 280:28451-28462.
61. Jones E.G., Tighilet B., Tran B.V., Huntsman M.M. Nucleus- and cell-specific expression of NMDA and non-NMDA receptor subunits in monkey thalamus. J Comp Neurol 1998, 397:371-393.
62. Kwon J.S., O'Donnell B.F., Wallenstein G.V., Greene R.W., Hirayasu Y., Nestor P.G., et al. Gamma frequency-range abnormalities to auditory stimulation in schizophrenia. Arch Gen Psychiatry 1999, 56:1001-1005.
63. 2+ ions in nicotinic facilitation of GABA release in mouse thalamus. J Neurosci 1997, 17:576-585.
64. Levin E.D., Simon B.B. Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology (Berl) 1998, 138:217-230.
65. West A.R., Grace A.A. The role of frontal-subcortical circuits in the pathophysiology of schizophrenia. Frontal-subcortical circuits in psychiatric and neurological disorders 2001, 372-400. Guilford Publications, New York, NY. D.G. Lichter, J.L. Cummings (Eds.).
66. Balla A., Koneru R., Smiley J., Sershen H., Javitt D.C. Continuous phencyclidine treatment induces schizophrenia-like hyperreactivity of striatal dopamine release. Neuropsychopharmacology 2001, 25:157-164.
67. Thompson J.L., Pogue-Geile M.F., Grace A.A. Developmental pathology, dopamine, and stress: a model for the age of onset of schizophrenia symptoms. Schizophr Bull 2004, 30:875-900.
68. Grace A.A., Bunney B.S., Moore H., Todd C.L. Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs. Trends Neurosci 1997, 20:31-37.
69. Radcliffe K.A., Dani J.A. Nicotinic stimulation produces multiple forms of increased glutamatergic synaptic transmission. J Neurosci 1998, 18:7075-7083.
70. Buccafusco J.J., Letchworth S.R., Bencherif M., Lippiello P.M. Long-lasting cognitive improvement with nicotinic receptor agonists: mechanisms of pharmacokinetic-pharmacodynamic discordance. Trends Pharmacol Sci 2005, 26:352-360.
71. Olincy A., Harris J.G., Johnson L.L., Pender V., Kongs S., Allensworth D., et al. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 2006, 63:630-638.
72. Dunbar G., Hosford D., Segreti A., Lieberman J. Effects of alpha7 nicotinic receptor agonist TC-5619 in cognitive dysfunction in schizophrenia. J Neuropsychopharm 2011, 21:S522.